Beta cell function in type 1 diabetes determined from clinical and fasting biochemical variables

Area of Science:

• Endocrinology
• Metabolic Diseases
• Clinical Trials

Background:

• Beta cell function is crucial in type 1 diabetes (T1D) management.
• Current assessment involves a 2-hour mixed-meal test (CP_AVE), which is complex and costly.
• A simpler, more accessible measure is needed for monitoring disease progression and therapy response.

Purpose of the Study:

• To determine if average plasma C-peptide concentration (CP_AVE) can be reliably estimated from routine clinical variables.
• To develop and validate a model for estimating beta cell function in T1D.
• To assess the utility of this estimation in clinical practice and research.

Main Methods:

• Linear models were developed using clinical and fasting biochemical data from eight randomized therapy trials in recently diagnosed T1D participants.
• Models were validated for accuracy in estimating beta cell function loss and response to immune therapy.
• Key variables included disease duration, BMI, insulin dose, HbA_1c, fasting plasma C-peptide, and fasting plasma glucose.

Main Results:

• A model using six routine variables (CP_EST) accurately estimated beta cell function loss (AUROC 0.89).
• CP_EST outperformed the insulin-dose-adjusted HbA_1c (IDAA1c) measure (AUROC 0.72).
• CP_EST reliably identified treatment effects in trials, requiring only a modest increase in sample size for equivalent statistical power compared to CP_AVE.

Conclusions:

• Estimated C-peptide (CP_EST), derived from six variables at a single time point, accurately reflects beta cell function in T1D.
• CP_EST is comparable to CP_AVE for assessing treatment effects and could serve as a convenient, economical measure.
• This method is suitable for clinical use and as a primary outcome in T1D therapeutic trials.